Mast cell activation symptoms are prevalent in Long-COVID

Autor: Leonard B. Weinstock, Jill B Brook, Arthur S. Walters, Lawrence B. Afrin, Gerhard J. Molderings, Ashleigh J. Goris
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Microbiology (medical)
Adult
Male
Coronavirus disease 2019 (COVID-19)
N
number
Mast Cell Activation Syndrome
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
BMI
body mass index
NS
not significant
Population
Mast cell activation syndrome
Infectious and parasitic diseases
RC109-216
Article
Post-Acute COVID-19 Syndrome
MC
mast cell
MCMRS
mast cell mediator release syndrome
Quality of life
mast cell activation
medicine
Humans
Mast Cells
education
education.field_of_study
Mast cell activation
business.industry
SARS-CoV-2
COVID-19
General Medicine
Long-COVID
Middle Aged
Pathophysiology
MCs
mast cells
Online assessment
OR
odds ratio
Infectious Diseases
MCA
mast cell activation
CI
confidence intervals
Immunology
MCAS
mast cell activation syndrome
Quality of Life
Female
fatigue
medicine.symptom
business
SD
standard deviation
Zdroj: International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 112, Iss, Pp 217-226 (2021)
ISSN: 1878-3511
1201-9712
Popis: Objectives Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC. Methods Adults in LC-focused Facebook support groups were recruited for online assessment of symptoms before and after COVID-19. Questions included presence and severity of known MCA and LC symptoms and validated assessments of fatigue and quality of life. General population controls and mast cell activation syndrome (MCAS) patients were recruited for comparison if they were ≥18 years of age and never had overt COVID-19 symptoms. Results There were 136 LC subjects (89.7% females, age 46.9 ±12.9 years), 136 controls (65.4% females, age 49.2 ±15.5), and 80 MCAS patients (85.0% females, age 47.7 ±16.4). Pre-COVID-19 LC subjects and controls had virtually identical MCA symptom and severity analysis. Post-COVID-19 LC subjects and MCAS patients prior to treatment had virtually identical MCA symptom and severity analysis. Conclusions MCA symptoms were increased in LC and mimicked the symptoms and severity reported by patients who have MCAS. Increased activation of aberrant mast cells induced by SARS-CoV-2 infection by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to effective therapy.
Databáze: OpenAIRE
Externí odkaz: